1. Executive Session 6:00 - 6:30

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:40
   - Updates

4. Medical Director Update 6:40 – 6:45
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:45 – 7:00
   - Multiple benzo analysis including sedative/hypnotic(Z drugs)-Z drugs quantity limits
   - Advair Diskus Criteria
   - Updated GI Agents Criteria- dicyclomine

6. RetroDUR/DUR 7:00 – 7:20
   - 2016 RetroDUR Initiatives

7. Clinical Update: Drug Reviews 7:20 – 7:45
   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - Harvoni® Tab (ledipasvir & sofosbuvir combination)
   - Technivie® Tab (ombitasvir/paritaprevir/ritonavir and dasabuvir tabs)
   - Viekira® Pak (ombitasvir, paritaprevir & ritonavir tabs; dasabuvir tabs)

   Full New Drug Reviews
   - Rexulti® Tab (brexpiprazole)
   - Entresto® Tab (valsartan/sacubitril)

8. Therapeutic Drug Classes – Periodic Review 7:45 – 8:15
   (Public comment prior to Board action)
   - Acne
   - Antibiotics, GI
9. **New Managed Therapeutic Drug Classes**
   (Public comment prior to Board action)

10. **Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products**
    (Public comment prior to Board action)

11. **General Announcements**
    Selected FDA Safety Alerts

   FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections

   FDA announces Glades Drugs’ nationwide voluntary recall of Compound Multivitamins containing High Amounts of Vitamin D3 (Cholecalciferol)
   [http://www.fda.gov/drugs/drugsafety/ucm474552.htm](http://www.fda.gov/drugs/drugsafety/ucm474552.htm)

   FDA takes action to protect consumers from potentially dangerous dietary supplements
   [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473099.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473099.htm)

   FDA Drug Safety Communication: FDA advises of rare cases of underactive thyroid in infants given iodine-containing contrast agents for medical imaging

12. **Adjourn**